The immunomodulatory drug lenalidomide restores a vitamin D sensitive phenotype to the vitamin D resistant breast cancer cell line MDA-MB-231 through inhibition of BCL-2: potential for breast cancer therapeutics
2015 ◽
Keyword(s):
2020 ◽
Vol 59
(6)
◽
pp. 828-834